Business Model in Practice: Platform Technology

Wednesday, 26 June 2024, 15:00 – 16:00 

Annette Galler | VP Portfolio Strategy, Scenic Biotech

She brings more than 20 years of experience in the Pharmaceutical and Biotech industry spanning almost the entire value chain from research, drug development, licensing up to launch and commercialization.

Prior to joining Scenic Biotech Annette was Chief Development Officer at T-Balance Therapeutics. Previously, she successfully led global development programs in immunology and oncology at a top 20 global pharmaceutical company. In this role she also headed several due diligence projects and was an integral member of licensing and negotiation teams. In addition, Annette has a strong commercial background including successful launches and re-launches in the specialty care market.

Annette holds a PhD in biochemistry and is co-inventor on patents for the treatment of inflammatory diseases.

Business Model in Practice: Platform Technology

• Scenic Biotech is pioneering genetic modifiers or so called “disease suppressors” for drug discovery to build a pipeline of breakthrough products. Founded in 2017 as a spin-out from the Netherlands Cancer Institute and Oxford University, Scenic Biotech is advancing a pipeline of pre-clinical discovery programs that utilize a revolutionary genetics approach to identify novel drug targets across a wide range of diseases. This session will explore Scenic Biotech's platform technology and its unique methodology for discovering genetic modifiers that can suppress disease phenotypes. Participants will learn how this innovative approach opens new possibilities for treating rare genetic disorders and advancing immuno-oncology therapies.